The medication's therapeutic effects depend on consistent administration and gradual dose escalation rather than the specific day of initiation
For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse cardiovascular events (MACE heart attack, stroke, or cardiovascular death) by 20% compared to placebo (HR 0.80
Omzo's own published disclosures state: "Individual results may vary
I gained 18 pounds over the 16 weeks, and when I had my body composition tested at the end, I had added 14 pounds of lean tissue while only gaining 4 pounds of fat
These findings suggest that while bitter substances promise to improve glucose homeostasis, their potential adverse effects beyond the gastrointestinal system warrant careful consideration [196]
Ozempic and Wegovy have joined a list of medications subject to price negotiations for Medicare Part D, which could put more pressure on revenues